FACS assay shows that recombinant Human OX40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OX0-H5252) can bind to 293T cell overexpressing human OX40L. The concentration of OX40 is 0.01 μg/mL (Routinely tested).
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| OX0-M82E5 | Mouse | Biotinylated Mouse OX40 / TNFRSF4 / CD134 Protein, His,Avitag™ |  |
|
|
| OX0-H5252 | Human | Human OX40 / TNFRSF4 / CD134 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| OX0-M522b | Marmoset | Marmoset OX40 / TNFRSF4 / CD134 Protein, His Tag |  |
|
|
| TN4-H82E4 | Human | Biotinylated Human OX40 / TNFRSF4 / CD134 Protein, Avitag™,His Tag (recommended for biopanning) |  |
|
|
| OX0-R5253 | Rat | Rat OX40 / TNFRSF4 / CD134 Protein, Fc Tag |  |
|
|
| OX0-R5254 | Rabbit | Rabbit OX40 / TNFRSF4 / CD134 Protein, Fc Tag |  |
|
|
| OX0-H82F7 | Human | Biotinylated Human OX40 Protein, Fc,Avitag™ |  |
|
|
| OX0-C5251 | Rhesus macaque | Rhesus macaque OX40 / TNFRSF4 / CD134 Protein, Fc Tag |  |
|
|
| OX0-C5220 | Rhesus macaque | Rhesus macaque OX40 / TNFRSF4 / CD134 Protein, His Tag |  |
|
|
| OX0-M5259 | Mouse | Mouse OX40 / TNFRSF4 / CD134 Protein, Fc Tag |  |
|
|
| OX0-M5228 | Mouse | Mouse OX40 / TNFRSF4 / CD134 Protein, His Tag |  |
|
|
| OX0-H5224 | Human | Human OX40 / TNFRSF4 / CD134 Protein, His Tag |  |
|
|
| OX0-H5255 | Human | Human OX40 / TNFRSF4 / CD134 Protein, Fc Tag |  |
|
|
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| INCAGN-1949 | INCAGN-1949 | Phase Ⅱ | Agenus, Ludwig Institute for Cancer Research, Incyte | Urogenital cancer, Renal cell carcinoma, Solid tumours | Details |
| BGB-A445 | BGB-A445 | Phase Ⅰ | BeiGene | Solid tumours | Details |
| Efizonerimod alfa | MEDI-6383,MEDI6383 | Phase Ⅰ | MedImmune | Solid tumours | Details |
| GSK3174998 | GSK-3174998; GSK 3174998; GSK3174998 | Phase Ⅱ | GlaxoSmithKline | Solid tumours, Head and neck cancer | Details |
| FS-120 | FS-120 | IND Filing | F-star | Cancer | Details |
| PF-04518600 | PF-04518600; PF-8600 | Phase Ⅱ | Pfizer | Renal cell carcinoma, Breast cancer, Solid tumours | Details |
| SL-279252 | SL-279252; TAK-252 | Phase Ⅰ | Shattuck Labs | Gastric adenocarcinoma, Non small cell lung cancer (NSCLC), Diffuse large B cell lymphoma, Renal cell carcinoma, Urothelial cancer, Solid tumours, Squamous cell carcinoma of head and neck cancer (SCCHN), Hodgkin lymphoma, Gastroesophageal junction adenocarcinoma, Melanoma | Details |
| INBRX-106 | INBRX-106 | Phase Ⅰ | Inhibrx | Solid tumours | Details |
| BMS-986178 | BMS-986178 | Phase Ⅱ | Bristol-Myers Squibb | Solid tumours | Details |
| Recombinant human anti-OX40 monoclonal antibody (Livzon Group) | Phase Ⅰ | Livzon Pharmaceutical Group | Cancer | Details | |
| MEDI-6469 | MEDI-6469 | Phase Ⅱ | AgonOx, Providence Cancer Center, MedImmune | Diffuse large B cell lymphoma, Prostate cancer, Breast cancer, Colorectal cancer, Head and neck cancer, Melanoma | Details |
| Recombinant human anti-OX40 monoclonal antibody (Innovent Biologics) | IBI-101,IBI101 | Phase Ⅰ | Innovent Biologics | Cancer | Details |
| KHK-4083 | KHK-4083 | Phase Ⅱ | Kyowa Hakko Kirin | Ulcerative colitis | Details |
| ATOR-1015 | ATOR-1015; ADC-1015 | Phase Ⅰ | Alligator Bioscience | Solid tumours | Details |
| Tavolimab | MEDI-0562,MEDI0562 | Phase Ⅱ | MedImmune | Ovarian cancer | Details |
| GBR-830 | GBR-830 | Phase Ⅱ | Glenmark Pharmaceuticals | Atopic dermatitis | Details |
| Vonlerolizumab | RO-7021608; MOXR-0916; RG-7888 | Phase Ⅱ | Genentech | Solid tumours | Details |
This web search service is supported by Google Inc.
A-Z